Literature DB >> 35338384

Integration of polyurethane meniscus scaffold during ACL revision is not reliable at 5 years despite favourable clinical outcome.

Hélder Pereira1,2,3,4, Ibrahim Fatih Cengiz5,6, Joana Silva-Correia5,6, Joaquim M Oliveira5,6, José C Vasconcelos7, Sérgio Gomes7, Pedro L Ripoll8, Jón Karlsson9,10,11, Rui L Reis5,6, João Espregueira-Mendes5,6,7.   

Abstract

PURPOSE: The aim of this study was to evaluate the clinical outcome at 5-year follow-up of a one-step procedure combining anterior cruciate ligament (ACL) reconstruction and partial meniscus replacement using a polyurethane scaffold for the treatment of symptomatic patients with previously failed ACL reconstruction and partial medial meniscectomy. Moreover, the implanted scaffolds have been evaluated by MRI protocol in terms of morphology, volume, and signal intensity.
METHODS: Twenty patients with symptomatic knee laxity after failed ACL reconstruction and partial medial meniscectomy underwent ACL revision combined with polyurethane-based meniscal scaffold implant. Clinical assessment at 2- and 5-year follow-ups included VAS, Tegner Activity Score, International Knee Documentation Committee (IKDC), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and the Lysholm Score. MRI evaluation of the scaffold was performed according to the Genovese scale with quantification of the scaffold's volume at 1- and 5-year follow-ups.
RESULTS: All scores revealed clinical improvement as compared with the preoperative values at the 2- and 5-year follow-ups. However, a slight, but significant reduction of scores was observed between 2 and 5 years. Concerning the MRI assessment, a significant reduction of the scaffold's volume was observed between 1 and 5 years. Genovese Morphology classification at 5 years included two complete resorptions (Type 3) and all the remaining patients had irregular morphology (Type 2). With regard to the Genovese Signal at the 5-year follow-up, three were classified as markedly hyperintense (Type 1), 15 as slightly hyperintense (Type 2), and two as isointense (Type 1).
CONCLUSION: Simultaneous ACL reconstruction and partial meniscus replacement using a polyurethane scaffold provides favourable clinical outcomes in the treatment of symptomatic patients with previously failed ACL reconstruction and partial medial meniscectomy at 5 years. However, MRI evaluation suggests that integration of the scaffold is not consistent. LEVEL OF EVIDENCE: Level IV.
© 2022. The Author(s) under exclusive licence to European Society of Sports Traumatology, Knee Surgery, Arthroscopy (ESSKA).

Entities:  

Keywords:  ACL revision; Anterior cruciate ligament; Meniscus; Meniscus scaffold

Mesh:

Substances:

Year:  2022        PMID: 35338384     DOI: 10.1007/s00167-022-06946-z

Source DB:  PubMed          Journal:  Knee Surg Sports Traumatol Arthrosc        ISSN: 0942-2056            Impact factor:   4.114


  4 in total

1.  Revision anterior cruciate ligament reconstruction: causes of failure, surgical technique, and clinical results.

Authors:  Matteo Denti; Dario Lo Vetere; Corrado Bait; Herbert Schönhuber; Gianluca Melegati; Piero Volpi
Journal:  Am J Sports Med       Date:  2008-06-20       Impact factor: 6.202

Review 2.  No differences in clinical outcome between CMI and Actifit meniscal scaffolds: a systematic review and meta-analysis.

Authors:  Davide Reale; Davide Previtali; Luca Andriolo; Alberto Grassi; Christian Candrian; Stefano Zaffagnini; Giuseppe Filardo
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2021-04-16       Impact factor: 4.342

3.  Comment on Medial Meniscus Scaffold Implantation in Combination with Concentrated Bone Marrow Aspirate Injection: Minimum 3-Year Follow-Up.

Authors:  Mingjin Zhong; Wei Lu; Weimin Zhu
Journal:  J Knee Surg       Date:  2020-11-09       Impact factor: 2.501

Review 4.  Meniscal Transplants and Scaffolds: A Systematic Review of the Literature.

Authors:  Sean Dangelmajer; Filippo Familiari; Roberto Simonetta; Mehmet Kaymakoglu; Gazi Huri
Journal:  Knee Surg Relat Res       Date:  2017-03-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.